The Chemo + PD-L1 + Anlo regimen has demonstrated improvements in PFS and ORR with comparable toxicity, making it a first-line option for ES-SCLC; however, it cannot fully replace the current immunochemotherapy due to a lack of OS improvement. This evidence concerns the gene CD274 and small cell lung carcinoma.